Bronchiectasis Linked to Increased NTM Infection Risk

Research indicates that bronchiectasis significantly increases the risk of nontuberculous mycobacteria (NTM) infection. According to a bidirectional Mendelian randomization analysis using genome-wide association data across two independent datasets, the structural lung damage associated with bronchiectasis may silently drive the risk of developing these infections.

The relationship between these two respiratory conditions is described as bidirectional, meaning each can contribute to the development or progression of the other. While bronchiectasis increases the likelihood of NTM infection, evidence also suggests that NTM infections can cause bronchiectasis.

The Bidirectional Link Between NTM and Bronchiectasis

A meta-analysis based on two datasets found that NTM infection was associated with an increased risk of bronchiectasis, reporting an odds ratio (OR) of 1.05 (95% CI: 1.01-1.08; p < 0.05). This suggests a causal link where the infection itself contributes to the permanent widening of the airways.

Conversely, bronchiectasis creates a physiological environment that favors the colonization of NTM. According to a narrative review published on April 23, 2025, in Health Science Reports, bronchiectasis can create a favorable environment for NTM colonization and exacerbate the progression of NTM.

Because of this interplay, managing patients often requires a comprehensive medical approach. Clinicians must address both the active infection and the underlying structural damage to the lungs to prevent further deterioration.

Risk Factors and Pathophysiology

The risk factors for NTM infection are inherently linked to the mechanisms of bronchiectasis. Research published in the European Respiratory Review on July 3, 2024, identifies several key factors that contribute to this vulnerability.

These factors include:

• Disorders of mucociliary clearance, which hinder the lungs’ ability to clear mucus and trapped particles.
• Alterations in the consistency of airway mucus.
• The presence of connective tissue disorders.
• Compromised immune responses.

When the lungs cannot effectively clear mucus, it creates a stagnant environment where mycobacteria can settle and grow. This synergy between structural lung dysfunction and bacterial colonization often leads to a cycle of chronic infection and further airway damage.

Clinical Implications and Management

The discovery that bronchiectasis may drive NTM infection risk highlights the importance of monitoring patients with structural lung disease for signs of mycobacterial colonization. Because these infections can be “silent” or hidden, genetic evidence and clinical screening are vital for early detection.

For individuals with non-cystic fibrosis (non-CF) bronchiectasis, other health factors may also influence outcomes. Reporting from AJMC indicates that a higher body mass index (BMI) has been linked to a lower mortality rate and fewer complications in this specific patient population.

the interaction between NTM and bronchiectasis underscores the complexity of chronic respiratory care. Treatment strategies must account for the fact that NTM-related bronchiectasis is often observed in individuals with specific risk factors, including a prior history of NTM lung infections or other chronic respiratory conditions.